# EXUMA Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exuma-biotech

- Industry: Biotechnology
- Headquarters: West Palm Beach, US
- Website: www.exumabio.com
- Total disclosed funding: $97M
- Latest round: Series B (Dec 21, 2021)
- Investors on record: 6

## About

EXUMA Biotech Corp. focuses on developing innovative cell and gene therapies for treating autoimmune diseases and various cancers, enhancing patient care through advanced therapeutic platforms.EXUMA Biotech Corp. was founded in 2015 in West Palm Beach, US. The company specializes in cell and gene therapy solutions and has executed 4 deals, with its most recent funding round being a Series B in December 2021, raising USD 41.000 mn led by Americo Life. The firm has a current valuation of USD 169.472 mn. Gregory Frost is the CEO of the company.EXUMA Biotech specializes in the development of innovative cell and gene therapies aimed at treating autoimmune diseases and various forms of cancer. The company's primary offerings include the rPOC Subcutaneous (SC) platform, engineered for the administration of autologous cell therapies without necessitating lymphodepleting chemotherapy. This technology allows for the reprogramming of a patient's own lymph nodes to facilitate in vivo CAR-T therapy, enhancing the efficacy and safety of treatment. EXUMA has also developed a CD3-Targeted lentivector that selectively targets and loads lymphocytes for subsequent transduction and expansion, alongside its FITNESS DRIVER transgene which optimizes effector cell characteristics. The products are primarily aimed at healthcare providers in North America and Europe, catering to hospitals, research institutions, and specialized oncology clinics.EXUMA Biotech generates revenue through a combination of partnerships and collaborations with healthcare providers and research institutions. The transaction structure typically involves direct agreements for the provision of their proprietary therapies, particularly focusing on their flagship product lines such as the TMR CAR-T product. Clients enter into contracts that outline the terms for usage and distribution of these therapies, often based on patient needs. Revenue streams include potential licensing agreements for their technologies and ongoing collaborations for clinical research. Pricing details for specific therapies are established as part of these agreements, reflecting the advanced nature of the treatments and their potential impact on patient outcomes.In December 2021, EXUMA Biotech raised USD 41.000 mn in Series B funding, led by Americo Life, with participation from F1 BioVentures, MSD Partners, Shanghai Sinobioway Sunterra Biotechnology Co., Ltd, Sinobioway Medicine, and SunTerra Capital. The funds will be utilized to further develop EXUMA's autologous subcutaneous rPOC CAR-TaNK platform targeting hematologic and solid tumors, as well as to continue clinical investigations of the Tumor Metabolism Regulated (TMR) CAR technology aimed at solid tumors. The company plans to expand into new markets, particularly in Europe and Asia, by the end of 2023.

## Funding rounds

- Series B, Dec 21, 2021, $41M — Americo Life, Sinobioway Medicine, F1 BioVentures, SunTerra Capital, BDT & MSD Partners, Shanghai Sinobioway Sunterra Biotechnology Co., Ltd
- Series B, Jan 3, 2020, $19M — F1 BioVentures, BDT & MSD Partners
- Series A, Jan 6, 2017, $37M — Sinobioway Medicine, F1 BioVentures, SunTerra Capital

## Investors

- Sinobioway Medicine — Series A, Series B
- F1 BioVentures (https://capitalatlas.ai/funds/f1-bioventures) — Series A, Series B
- SunTerra Capital — Series A, Series B
- BDT & MSD Partners (https://capitalatlas.ai/funds/bdt-msd-partners) — Series B
- Americo Life — Series B
- Shanghai Sinobioway Sunterra Biotechnology Co., Ltd — Series B